ABSTRACT
Humans respond differently toward exposure against pathogens and some individuals are completely resistant against transmission due to a genetically determined susceptibility. A rising number of such, so-called, host factors have been described during the last years, but their role for diagnostic or therapeutic application is still to be clarified. Here, we describe the biology of the chemokine receptor CCR5 and its polymorphism in the context of host adaptation and immune system function. Furthermore, the first clinical applications exploiting our knowledge of this chemokine receptor as a host factor are described.
Subject(s)
Polymorphism, Genetic , Receptors, CCR5/genetics , CCR5 Receptor Antagonists , Communicable Diseases/genetics , Communicable Diseases/immunology , Gene Frequency , Genetic Predisposition to Disease , HIV Infections/genetics , HIV Infections/immunology , HumansABSTRACT
Today, 30 years after the onset of the HIV pandemic, although treatment strategies have considerably improved, there is still no cure for the disease. Recently, we described a successful hematopoietic stem cell transplantation in an HIV-1-infected patient, transferring donor-derived cells with a natural resistance against HIV infection. These hematopoietic stem cells engrafted, proliferated, and differentiated into mature myeloid and lymphoid cells. To date, the patient has not required any antiretroviral treatment, more than 4 years after allogeneic transplantation. In the analysis of peripheral blood cells and different tissue samples, including gut, liver, and brain, no viral load or proviral DNA could be detected. Our report raises the hope for further targeted treatment strategies against HIV and represents a successful personalized treatment with allogeneic stem cells carrying a beneficial gene. However, this case has ignited a controversy regarding the question of whether this patient has achieved complete eradication of HIV or not. Here we give an update on open questions, unsolved aspects, and clinical consequences concerning this unique case.
Subject(s)
HIV Infections/therapy , Hematopoietic Stem Cell Transplantation , Receptors, CCR5/genetics , Combined Modality Therapy , HIV Infections/complications , HIV Infections/genetics , HIV Infections/immunology , HIV-1/immunology , HIV-1/pathogenicity , Humans , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/therapy , RNA, Viral/blood , Sequence Deletion , Transplantation Conditioning , Transplantation, HomologousABSTRACT
Infection with the human immunodeficiency virus type 1 (HIV-1) requires the presence of a CD4 receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Homozygosity for a 32-bp deletion in the CCR5 allele provides resistance against HIV-1 acquisition. We transplanted stem cells from a donor who was homozygous for CCR5 delta32 in a patient with acute myeloid leukemia and HIV-1 infection. The patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy. This outcome demonstrates the critical role CCR5 plays in maintaining HIV-1 infection.
Subject(s)
HIV Infections/therapy , HIV-1 , Receptors, CCR5/genetics , Stem Cell Transplantation , Adult , Anti-Retroviral Agents/therapeutic use , CD4 Antigens , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , DNA, Viral/blood , Genetic Predisposition to Disease , HIV Infections/drug therapy , HIV Infections/immunology , HIV-1/genetics , Homozygote , Humans , Male , RNA, Viral/blood , Transplantation Chimera , Transplantation, Homologous , Viral LoadABSTRACT
OBJECTIVE: Changes of the peripheral blood cell count in patients with anorexia nervosa (AN) are frequent. Anemia and leukopenia are observed in one-third of these patients. Examination of the bone marrow reveals in almost 50% of the patients with AN signs of bone marrow atrophy and can additionally suffer from a gelatinous bone marrow transformation. METHOD: Published studies and investigations concerning hematological changes in patients with AN were reviewed. RESULTS: Anemia and mild neutropenia are detectable in almost one-third of these patients, whereas thrombocytopenia is rather uncommon. The exact mechanism for these findings is still unclear, but 50% of AN-patients with hematological changes display morphological signs of partial bone marrow atrophy. DISCUSSION: Changes of the peripheral blood cell count in patients with AN is a frequent observation but the peripheral blood cell count cannot predict the severity of bone marrow atrophy. All hematological and morphological alterations disappear completely and rapidly after sufficient refeeding.
Subject(s)
Anemia/etiology , Anorexia Nervosa/blood , Anorexia Nervosa/complications , Bone Marrow/pathology , Neutropenia/etiology , Anemia/blood , Anemia/epidemiology , Anorexia Nervosa/pathology , Atrophy , Blood Cell Count , Erythropoiesis , Glycosaminoglycans/analysis , Humans , Neutropenia/blood , Neutropenia/epidemiology , Thrombocytopenia/blood , Thrombocytopenia/epidemiology , Thrombocytopenia/etiologyABSTRACT
Although ATG is frequently used in hematopoietic stem cell transplantation and solid organ transplantation, little is known on its effects on NK cells, which mediate important functions in post-transplantation immunology. We incubated peripheral blood lymphocytes of healthy donors with Thymoglobulin, Lymphoglobulin or ATG-Fresenius. Cell death and apoptosis of NK cells and T cells were determined by flow cytometry using propidium iodide and Annexin V. As expected, there were no significant differences between the different ATGs regarding their T cell toxicity. Surprisingly, we found profound differences between the different ATGs regarding their impact on NK cells: In clinically relevant concentrations Lymphoglobulin had less toxic effects on NK cells as compared to Thymoglobulin or ATG-Fresenius: the median percentages of apoptotic or necrotic NK cells in response to 1 mug/ml Lymphoglobulin, ATG-Fresenius and Thymoglobulin were 2%, 35% and 38%, respectively (p<0.001). This is the first report of differential effects of different ATGs on NK cells. Lymphoglobulin appears to be superior to Thymoglobulin or ATG Fresenius regarding the preservation of NK cell mediated immunity. Randomized trials addressing the impact of different ATGs on lymphocyte subpopulations in the clinical setting are urgently warranted.
Subject(s)
Antibodies, Monoclonal/pharmacology , Antilymphocyte Serum/pharmacology , Immunoglobulins/pharmacology , Killer Cells, Natural/drug effects , Annexin A5/chemistry , Apoptosis/drug effects , Cell Death/drug effects , Hematopoietic Stem Cell Transplantation/methods , Humans , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Propidium/chemistry , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Transplantation ImmunologyABSTRACT
The antitumor activity of natural killer (NK) cells has recently been shown to be assessable at a single-cell level via flow cytometric detection of CD107a. We used this novel method to prospectively quantify and characterize tumor-reactive NK cells in patients undergoing myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic stem cell transplantation (HSCT). Degranulation of NK cells in the peripheral blood of 34 patients after HSCT (day +30, day +90) was determined by evaluating CD107a expression after coincubation of the cells with tumor targets. The percentage of degranulating NK cells was higher after nonmyeloablative conditioning than after myeloablative conditioning (P<.001), indicating a higher activation state and increased antitumor activity of NK cells after nonmyeloablative conditioning. We were able to analyze NK cell subsets separately and found that CD56bright NK cells following HSCT are functionally different from CD56bright NK cells in healthy donors, as indicated by a high percentage of degranulating NK cells in response to tumor targets in patients after HSCT. The CD107a assay is a new and feasible method to quantify and characterize tumor-reactive NK cells after HSCT. Using this method, we found that NK cells had high antitumor cytotoxic activity after nonmyeloablative conditioning, which may contribute to the effectiveness of nonmyeloablative conditioning.